Dementia Associated with Alzheimer`s Disease

Global Dementia Associated with Alzheimer`s Disease Market to Reach US$8.0 Billion by 2030

The global market for Dementia Associated with Alzheimer`s Disease estimated at US$6.6 Billion in the year 2024, is expected to reach US$8.0 Billion by 2030, growing at a CAGR of 3.4% over the analysis period 2024-2030. Cholinergic / Cholinesterase Inhibitors, one of the segments analyzed in the report, is expected to record a 4.5% CAGR and reach US$3.3 Billion by the end of the analysis period. Growth in the Memantine segment is estimated at 2.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.8 Billion While China is Forecast to Grow at 6.5% CAGR

The Dementia Associated with Alzheimer`s Disease market in the U.S. is estimated at US$1.8 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.6 Billion by the year 2030 trailing a CAGR of 6.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.3% and 2.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.9% CAGR.

Global Dementia Associated With Alzheimer’s Disease Market – Key Trends & Drivers Summarized

Why Is Alzheimer’s-Associated Dementia Emerging as a Central Public Health Challenge Worldwide?

Dementia associated with Alzheimer’s disease (AD) represents the most prevalent form of cognitive decline globally, accounting for nearly 60% to 80% of all dementia diagnoses. Characterized by progressive neurodegeneration, memory loss, language impairment, and executive dysfunction, Alzheimer’s-related dementia imposes an immense burden on patients, caregivers, and health systems. As global life expectancy increases and aging populations expand—particularly in high-income and upper-middle-income countries—Alzheimer’s dementia is fast becoming one of the most pressing public health crises of the 21st century.

Unlike other chronic conditions, dementia care requires continuous cognitive, behavioral, and functional management, making it not only a medical issue but a profound socioeconomic challenge. The shift from acute treatment to long-term cognitive support has intensified demand for multidisciplinary care pathways, disease-modifying therapies, early diagnostic tools, and caregiver interventions. Consequently, the Alzheimer’s-associated dementia market is undergoing transformation—driven by innovation, demographic shifts, and policy realignment across aging economies.

What Innovations Are Transforming Diagnosis, Disease Modulation, and Patient Management?

The diagnostic landscape for Alzheimer’s dementia is being reshaped by advances in neuroimaging, fluid biomarkers, and cognitive assessment technologies. PET scans for amyloid-beta and tau deposition, along with MRI-based volumetric analysis, are enabling earlier and more definitive diagnoses. Additionally, cerebrospinal fluid (CSF) assays and emerging blood-based biomarkers such as plasma Aβ42/40 and phosphorylated tau are offering less invasive diagnostic alternatives—supporting broader screening and early intervention strategies.

On the therapeutic front, the emergence of disease-modifying treatments marks a significant departure from decades of symptomatic care. The FDA’s accelerated approval of monoclonal antibodies such as aducanumab and lecanemab, which target beta-amyloid accumulation, has ignited global interest in amyloid- and tau-directed therapies. Although efficacy debates persist, these approvals represent a paradigm shift toward slowing cognitive decline, rather than merely alleviating symptoms.

Digital therapeutics, virtual reality cognitive training, and AI-based monitoring platforms are gaining traction in managing mild-to-moderate dementia stages. Mobile apps, wearables, and ambient sensor systems are now being used to track patient behavior, detect anomalies, and support medication adherence. Pharmacological advancements are also underway in neuroinflammation modulators, synaptic function enhancers, and neuroprotective agents aimed at halting or reversing neuronal loss.

Who Are the Key Stakeholders and How Are Care Delivery Models Evolving Globally?

The Alzheimer’s dementia ecosystem includes pharmaceutical companies, biotechnology innovators, diagnostic developers, neurologists, geriatric specialists, memory clinics, assisted living facilities, health insurers, and patient advocacy groups. Government agencies, public health organizations, and academic research institutions also play instrumental roles in funding trials, generating longitudinal datasets, and shaping treatment guidelines.

Regionally, North America leads in therapeutic innovation, supported by strong R&D infrastructure, regulatory frameworks, and advanced care delivery models. The U.S. Centers for Medicare & Medicaid Services (CMS) and NIH-backed initiatives like the Accelerating Medicines Partnership (AMP-AD) have catalyzed biomarker development and patient registry expansions. In Europe, coordinated dementia strategies under the European Union’s Horizon Europe program are fostering cross-border collaboration in diagnostics and long-term care models.

Asia-Pacific is experiencing rapid growth in patient numbers due to demographic aging, especially in Japan, South Korea, and China. These regions are investing in memory care units, family-based caregiver training, and culturally tailored digital cognitive therapies. In emerging economies, Alzheimer’s dementia remains underdiagnosed and undertreated, though initiatives by the WHO and regional NGOs are improving awareness, community screening, and access to supportive care.

Multidisciplinary models of care—integrating neurology, psychiatry, occupational therapy, and social services—are being scaled through telemedicine platforms, memory clinics, and home-based health solutions. Caregiver support programs, respite care services, and caregiver education platforms are also gaining importance as families remain the primary source of dementia management globally.

What Is Driving the Growth in the Alzheimer’s-Associated Dementia Market Globally?

The growth in the Alzheimer’s-associated dementia market is driven by a confluence of aging demographics, increasing disease awareness, and advances in early diagnosis and therapeutic innovation. The global prevalence of Alzheimer’s dementia is projected to triple by 2050, especially in countries with rapidly aging populations and inadequate geriatric infrastructure. This trajectory is prompting urgent investments in healthcare capacity building, public health surveillance, and pharmacological innovation.

Breakthroughs in biomarker validation and precision diagnostics are improving clinical trial design, patient stratification, and treatment personalization—reducing attrition rates and enhancing regulatory confidence in disease-modifying drug candidates. The rise in public and private sector funding, spurred by advocacy from organizations like the Alzheimer’s Association, is sustaining a robust pipeline of therapeutic candidates and digital solutions.

Furthermore, the economic burden of Alzheimer’s dementia—reflected in productivity loss, caregiver stress, institutionalization costs, and health system strain—is motivating governments to develop national dementia strategies, reimbursement models, and long-term care insurance frameworks. As new therapies transition from trial to clinic, and as digital and biological tools converge, the market is expected to transition from symptom relief to disease interception, paving the way for a more proactive and integrated Alzheimer’s dementia care paradigm.

SCOPE OF STUDY:

The report analyzes the Dementia Associated with Alzheimer`s Disease market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Drug Class (Cholinergic / Cholinesterase Inhibitors, Memantine, Combined Drugs, Other Drug Classes); Distribution Channel (Hospital Pharmacies, Retail, Online Sales)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

• AbbVie, Inc.
• AC Immune SA
• Alector, Inc.
• AlphaCognition Inc.
• Araclon Biotech SL
• Axsome Therapeutics, Inc.
• Biogen, Inc.
• BioVie
• BioXcel Therapeutics
• Cognition Therapeutics

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.